TransCode Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO TransCode Therapeutics is Philippe Calais, benoemd in Oct2025, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde $ 7.49. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.4 jaar en 4.9 jaar.

Belangrijke informatie

Philippe Calais

Algemeen directeur

US$212.5k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.0001%
Management gemiddelde ambtstermijn	7.4yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15

CEO

Philippe Calais (66 yo)

less than a year

Tenure

US$212,535

Compensatie

Dr. Philippe P. Calais, Pharm. D. Ph.D. served as President, Chief Executive Officer and Director of MatriSys Bioscience, Inc. since January 13, 2024. Dr. Calais has been Executive Chairman of the Board of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Philippe Calais	CEO & Executive Chairman of the Board	less than a year	US$212.54k	0.00011% $ 7.5
Thomas Fitzgerald	CFO, President	7.4yrs	US$956.97k	0.00022% $ 15.0
Zdravka Medarova	Co-Founder & Chief Scientific Officer	9.9yrs	geen gegevens	geen gegevens
Anna Moore	Co-Founder	9.9yrs	geen gegevens	geen gegevens
Susan Duggan	Senior Vice President of Operations	no data	geen gegevens	geen gegevens
Daniel Vlock	Chief Medical Officer	1.8yrs	geen gegevens	geen gegevens

7.4yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RNAZ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philippe Calais	CEO & Executive Chairman of the Board	7.2yrs	US$212.54k	0.00011% $ 7.5
Thomas Fitzgerald	CFO, President	7.4yrs	US$956.97k	0.00022% $ 15.0
Anna Moore	Co-Founder	9.9yrs	geen gegevens	geen gegevens
Elizabeth Czerepak	Independent Director	less than a year	geen gegevens	geen gegevens
Phillip Zamore	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Magda Marquet	Independent Director	4.9yrs	US$62.54k	0% $ 0
Keith Flaherty	Member of Advisory Board	no data	geen gegevens	geen gegevens
Lubomir Nechev	Member of Advisory Board	4.8yrs	geen gegevens	geen gegevens
Frank Slack	Member of Advisory Board	3.3yrs	geen gegevens	geen gegevens
Dejan Juric	Member of Advisory Board	4.3yrs	geen gegevens	geen gegevens
Erik Manting	Independent Director	5yrs	US$60.54k	0% $ 0

4.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RNAZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/12/26 14:43
Aandelenkoers aan het einde van de dag	2025/12/26 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

TransCode Therapeutics, Inc. wordt gevolgd door 1 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Emily Bodnar	H.C. Wainwright & Co.

TransCode Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

TransCode Therapeutics, Inc., Annual General Meeting, Aug 29, 2025

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces Management Changes

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

Recent updates

TransCode Therapeutics Presents Preliminary Data from Its Completed Phase 1a Study with Tx-MC138 in Metastatic Disease at ESMO

TransCode Therapeutics, Inc. announced that it expects to receive $25.00146 million in funding

TransCode Therapeutics, Inc., Annual General Meeting, Aug 29, 2025

TransCode Therapeutics, Inc. Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial

TransCode Therapeutics, Inc. Reports Further Progress on Phase 1A Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.045 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split to Meet the Minimum Bid Price Requirement

TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Regain Compliance with Nasdaq Bid Price Requirement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Transcode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, A MicroRNA-Targeted Technology

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces Management Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

TransCode Therapeutics reports Q2 results

TransCode files U.S. patent application for radiotherapy based cancer treatment

Co-Founder recently bought US$55k worth of stock

TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology

TransCode Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

CEO

Leiderschapsteam